PT - JOURNAL ARTICLE AU - Martell, Danya J. AU - Merens, Hope E. AU - Fiorini, Claudia AU - Caulier, Alexis AU - Ulirsch, Jacob C. AU - Ietswaart, Robert AU - Choquet, Karine AU - Graziadei, Giovanna AU - Brancaleoni, Valentina AU - Domenica Cappellini, Maria AU - Scott, Caroline AU - Roberts, Nigel AU - Proven, Melanie AU - Roy, Noémi BA AU - Babbs, Christian AU - Higgs, Douglas R. AU - Sankaran, Vijay G. AU - Churchman, L. Stirling TI - RNA Polymerase II pausing temporally coordinates cell cycle progression and erythroid differentiation AID - 10.1101/2023.03.03.23286760 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.03.23286760 4099 - http://medrxiv.org/content/early/2023/03/07/2023.03.03.23286760.short 4100 - http://medrxiv.org/content/early/2023/03/07/2023.03.03.23286760.full AB - The controlled release of promoter-proximal paused RNA polymerase II (Pol II) into productive elongation is a major step in gene regulation. However, functional analysis of Pol II pausing is difficult because factors that regulate pause release are almost all essential. In this study, we identified heterozygous loss-of-function mutations in SUPT5H, which encodes SPT5, in individuals with β-thalassemia unlinked to HBB mutations. During erythropoiesis in healthy human cells, cell cycle genes were highly paused at the transition from progenitors to precursors. When the pathogenic mutations were recapitulated by SUPT5H editing, Pol II pause release was globally disrupted, and the transition from progenitors to precursors was delayed, marked by a transient lag in erythroid-specific gene expression and cell cycle kinetics. Despite this delay, cells terminally differentiate, and cell cycle phase distributions normalize. Therefore, hindering pause release perturbs proliferation and differentiation dynamics at a key transition during erythropoiesis, revealing a role for Pol II pausing in the temporal coordination between the cell cycle and differentiation.Competing Interest StatementV.G.S. serves as an advisor to and/or has equity in Branch Biosciences, Ensoma, Novartis, Forma, Sana Biotechnology, and Cellarity, all unrelated to the present work. J.C.U. is an employee of Illumina, Inc., unrelated to the present work. R.I. is a founder, board member and shareholder of Cellforma, unrelated to the present work.Funding StatementThis study was funded by the National Institute of Health Ruth L. Kirschstein Postdoctoral Fellowship F32-GM125238, National Science Foundation Graduate Research Fellowship DGE 1745303, EMBO fellowship ALTF 2016-422, NIH/NIGMS T32 postdoctoral training grant GM007748-44, Charity Action Medical Research grant GN2855, National Institutes of Health grants R01-HG007173, R01-DK103794, R01-HL146500, the New York Stem Cell Foundation (NYSCF), the Ellison Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Boston Children's Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.